Summit Therapeutics Inc.·4

Apr 9, 5:12 PM ET

DUGGAN ROBERT W 4

4 · Summit Therapeutics Inc. · Filed Apr 9, 2025

Insider Transaction Report

Form 4
Period: 2025-04-08
DUGGAN ROBERT W
DirectorCo-Chief Executive Officer10% Owner
Transactions
  • Exercise of In-Money

    Common Stock

    2025-04-08$1.58/sh+3,985,055$6,296,387555,680,151 total
  • Exercise of In-Money

    Warrant (right to buy)

    2025-04-08+3,985,0550 total
    Exercise: $1.58From: 2020-06-24Exp: 2029-12-24Common Stock (3,985,055 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    31,000
  • Common Stock

    (indirect: By Spouse)
    50,000
  • Common Stock

    (indirect: By Trust)
    10,199,776
  • Common Stock

    (indirect: By Trust)
    25,457,666
Footnotes (2)
  • [F1]On April 8, 2025, the Reporting Person exercised warrants to purchase an aggregate of 3,985,055 shares of the Issuer's common stock at an exercise price of $1.58 per share.
  • [F2]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Documents

1 file
  • 4
    wk-form4_1744233117.xmlPrimary

    FORM 4